L'exposition à la pollution, aux allergènes et aux irritants peut augmenter le risque d'asthme et de BPCO.
PollutionIrritants
#4
Quels sont les risques liés à l'âge ?
Les personnes âgées sont plus susceptibles de développer des maladies respiratoires comme la BPCO.
ÂgeBronchopneumopathie chronique obstructive
#5
Comment le stress influence-t-il l'asthme ?
Le stress peut aggraver les symptômes d'asthme en provoquant des réactions inflammatoires.
StressAsthme
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Association de furoate de mométasone et de fumarate de formotérol : Questions médicales les plus fréquentes",
"headline": "Association de furoate de mométasone et de fumarate de formotérol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Association de furoate de mométasone et de fumarate de formotérol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-17",
"dateModified": "2026-05-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Association de furoate de mométasone et de fumarate de formotérol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Association médicamenteuse",
"url": "https://questionsmedicales.fr/mesh/D004338",
"about": {
"@type": "MedicalCondition",
"name": "Association médicamenteuse",
"code": {
"@type": "MedicalCode",
"code": "D004338",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Association de furoate de mométasone et de fumarate de formotérol",
"alternateName": "Mometasone Furoate, Formoterol Fumarate Drug Combination",
"code": {
"@type": "MedicalCode",
"code": "D000068758",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hanns-Christian Tillmann",
"url": "https://questionsmedicales.fr/author/Hanns-Christian%20Tillmann",
"affiliation": {
"@type": "Organization",
"name": "Novartis Institutes for BioMedical Research, Translational Medicine, Basel, Switzerland. Electronic address: hanns-christian.tillmann@novartis.com."
}
},
{
"@type": "Person",
"name": "Soniya Vaidya",
"url": "https://questionsmedicales.fr/author/Soniya%20Vaidya",
"affiliation": {
"@type": "Organization",
"name": "Novartis Institutes for BioMedical Research, Cambridge, MA, USA; Current Affiliation: Axcella Health Inc., Cambridge, MA, USA."
}
},
{
"@type": "Person",
"name": "Paul Dorinsky",
"url": "https://questionsmedicales.fr/author/Paul%20Dorinsky",
"affiliation": {
"@type": "Organization",
"name": "AstraZeneca, Durham, NC, USA."
}
},
{
"@type": "Person",
"name": "Dave Singh",
"url": "https://questionsmedicales.fr/author/Dave%20Singh",
"affiliation": {
"@type": "Organization",
"name": "Medicines Evaluation Unit, Manchester University NHS Foundations Trust, Manchester, UK."
}
},
{
"@type": "Person",
"name": "Martin Jenkins",
"url": "https://questionsmedicales.fr/author/Martin%20Jenkins",
"affiliation": {
"@type": "Organization",
"name": "AstraZeneca, Cambridge, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Zein nanoparticles as oral carrier for mometasone furoate delivery.",
"datePublished": "2023-05-19",
"url": "https://questionsmedicales.fr/article/37208563",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s13346-023-01367-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Discussion of EMA Draft Guideline on Quality and Equivalence of Topical Products Based on Comparison of Approved Mometasone Furoate Drugs.",
"datePublished": "2024-07-12",
"url": "https://questionsmedicales.fr/article/38997617",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s13555-024-01222-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Multi-Gram Scale Synthesis and Characterization of Mometasone Furoate EP Impurity C.",
"datePublished": "2023-11-30",
"url": "https://questionsmedicales.fr/article/38067588",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules28237859"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.",
"datePublished": "2023-08-29",
"url": "https://questionsmedicales.fr/article/37583267",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/03007995.2023.2247969"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development of Niosomal Vesicles Loaded Mometasone Furoate Gel for Transdermal Delivery and its Evaluation.",
"datePublished": "2023-11-16",
"url": "https://questionsmedicales.fr/article/37974444",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2174/0126673878259437231031114907"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Préparations pharmaceutiques",
"item": "https://questionsmedicales.fr/mesh/D004364"
},
{
"@type": "ListItem",
"position": 3,
"name": "Association médicamenteuse",
"item": "https://questionsmedicales.fr/mesh/D004338"
},
{
"@type": "ListItem",
"position": 4,
"name": "Association de furoate de mométasone et de fumarate de formotérol",
"item": "https://questionsmedicales.fr/mesh/D000068758"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Association de furoate de mométasone et de fumarate de formotérol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Association de furoate de mométasone et de fumarate de formotérol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Association de furoate de mométasone et de fumarate de formotérol",
"description": "Comment diagnostiquer l'asthme ?\nQuels tests pour la BPCO ?\nQuels signes indiquent une exacerbation ?\nComment évaluer la gravité de l'asthme ?\nQuels examens pour les allergies respiratoires ?",
"url": "https://questionsmedicales.fr/mesh/D000068758#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Association de furoate de mométasone et de fumarate de formotérol",
"description": "Quels sont les symptômes de l'asthme ?\nComment reconnaître une crise d'asthme ?\nQuels symptômes de la BPCO ?\nQuels signes d'inflammation des voies respiratoires ?\nComment différencier asthme et BPCO ?",
"url": "https://questionsmedicales.fr/mesh/D000068758#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Association de furoate de mométasone et de fumarate de formotérol",
"description": "Comment prévenir les crises d'asthme ?\nQuelles mesures pour la BPCO ?\nComment gérer les allergies respiratoires ?\nQuel rôle joue l'éducation thérapeutique ?\nComment surveiller les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D000068758#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Association de furoate de mométasone et de fumarate de formotérol",
"description": "Comment fonctionne le furoate de mométasone ?\nQuel est le rôle du fumarate de formotérol ?\nComment utiliser l'association de médicaments ?\nQuels sont les effets secondaires possibles ?\nQuand consulter un médecin pour le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D000068758#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Association de furoate de mométasone et de fumarate de formotérol",
"description": "Quelles complications de l'asthme ?\nQuels risques liés à la BPCO ?\nComment prévenir les complications ?\nQuels effets à long terme de l'asthme non traité ?\nQuelles complications des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D000068758#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Association de furoate de mométasone et de fumarate de formotérol",
"description": "Quels facteurs de risque pour l'asthme ?\nComment le tabagisme affecte-t-il la BPCO ?\nQuel rôle joue l'environnement ?\nQuels sont les risques liés à l'âge ?\nComment le stress influence-t-il l'asthme ?",
"url": "https://questionsmedicales.fr/mesh/D000068758#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'asthme ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical, les tests de fonction pulmonaire et des examens physiques."
}
},
{
"@type": "Question",
"name": "Quels tests pour la BPCO ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la spirométrie et l'évaluation des symptômes respiratoires."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une exacerbation ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation de la dyspnée, de la toux et des expectorations peut signaler une exacerbation."
}
},
{
"@type": "Question",
"name": "Comment évaluer la gravité de l'asthme ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gravité est évaluée par la fréquence des symptômes et l'impact sur la vie quotidienne."
}
},
{
"@type": "Question",
"name": "Quels examens pour les allergies respiratoires ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests cutanés ou des dosages d'IgE spécifiques peuvent aider à identifier les allergies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de l'asthme ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent la toux, la respiration sifflante, la dyspnée et la sensation d'oppression thoracique."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une crise d'asthme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une crise se manifeste par une aggravation soudaine des symptômes respiratoires et une difficulté à respirer."
}
},
{
"@type": "Question",
"name": "Quels symptômes de la BPCO ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une toux chronique, une production de mucus et une dyspnée progressive."
}
},
{
"@type": "Question",
"name": "Quels signes d'inflammation des voies respiratoires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent une toux persistante, des sifflements et une respiration difficile."
}
},
{
"@type": "Question",
"name": "Comment différencier asthme et BPCO ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'asthme est souvent réversible, tandis que la BPCO est progressive et moins réactive aux bronchodilatateurs."
}
},
{
"@type": "Question",
"name": "Comment prévenir les crises d'asthme ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les déclencheurs connus, suivez le traitement et utilisez un inhalateur préventif."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour la BPCO ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez le tabac, suivez un programme d'exercices et recevez des vaccinations appropriées."
}
},
{
"@type": "Question",
"name": "Comment gérer les allergies respiratoires ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les allergènes, utilisez des antihistaminiques et suivez un traitement médical."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'éducation thérapeutique ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle aide les patients à comprendre leur maladie et à gérer leur traitement efficacement."
}
},
{
"@type": "Question",
"name": "Comment surveiller les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez un journal de symptômes et un débitmètre de pointe pour suivre votre état."
}
},
{
"@type": "Question",
"name": "Comment fonctionne le furoate de mométasone ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un corticostéroïde qui réduit l'inflammation dans les voies respiratoires."
}
},
{
"@type": "Question",
"name": "Quel est le rôle du fumarate de formotérol ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un bronchodilatateur qui relaxe les muscles des voies respiratoires pour améliorer la respiration."
}
},
{
"@type": "Question",
"name": "Comment utiliser l'association de médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est généralement administrée par inhalation, selon les prescriptions médicales."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires possibles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des infections respiratoires, des maux de tête et une irritation de la gorge."
}
},
{
"@type": "Question",
"name": "Quand consulter un médecin pour le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez si les symptômes s'aggravent ou si le traitement ne semble pas efficace."
}
},
{
"@type": "Question",
"name": "Quelles complications de l'asthme ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des crises sévères, des infections pulmonaires et des hospitalisations."
}
},
{
"@type": "Question",
"name": "Quels risques liés à la BPCO ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des exacerbations fréquentes, des infections et une insuffisance respiratoire."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier, un traitement adéquat et l'évitement des irritants sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels effets à long terme de l'asthme non traité ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un asthme non traité peut entraîner des dommages pulmonaires permanents et une qualité de vie réduite."
}
},
{
"@type": "Question",
"name": "Quelles complications des traitements ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent entraîner des effets secondaires comme la candidose buccale ou l'ostéoporose."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque pour l'asthme ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des allergies, et l'exposition à des irritants."
}
},
{
"@type": "Question",
"name": "Comment le tabagisme affecte-t-il la BPCO ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme est le principal facteur de risque, aggravant l'inflammation et la détérioration pulmonaire."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'environnement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'exposition à la pollution, aux allergènes et aux irritants peut augmenter le risque d'asthme et de BPCO."
}
},
{
"@type": "Question",
"name": "Quels sont les risques liés à l'âge ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées sont plus susceptibles de développer des maladies respiratoires comme la BPCO."
}
},
{
"@type": "Question",
"name": "Comment le stress influence-t-il l'asthme ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut aggraver les symptômes d'asthme en provoquant des réactions inflammatoires."
}
}
]
}
]
}
Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Publications dans "Association de furoate de mométasone et de fumarate de formotérol" :
Velocity Clinical Research Grosshansdorf, Airway Research Center North (ARCN), Formerly Pulmonary Research Institute at Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Wöhrendamm 80, 22927, Grosshansdorf, Germany. h.watz@pulmoresearch.de.
Publications dans "Association de furoate de mométasone et de fumarate de formotérol" :
Mometasone furoate (MF) is a synthetic glucocorticoid used clinically to treat specific inflammatory disorders including superior and inferior respiratory tract. Due to its poor bioavailability we fur...
Today, the approval for a generic topical product includes the presentation of therapeutic equivalence to the originator based on clinical trials. To facilitate this procedure, in 2018 the European Me...
To date, no data are available on the quality and evidence of the proposed test conditions. In this study, we performed an in vitro penetration test (IVPT) following the terms of the EMA draft guideli...
The complex biometric data processing revealed that in vitro equivalence could not be observed for all skin sections for either originator or generic product. Moreover, the necessity of the negative c...
This bioequivalence study shows insufficient parameters, which should be discussed together with the EMA draft guideline....
Mometasone furoate is a synthetic corticosteroid used in the treatment of skin inflammatory conditions, hay fever and asthma. The industrial manufacturing routes to mometasone furoate are generally ac...
Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. While two approved fixed-dose inhaled corticosteroid/long-acting muscarinic antagonist (LAMA)/long-acting β...
A systematic literature review identified two studies (ETHOS [NCT02465567]; IMPACT [NCT02164513]) of ≥52 weeks reporting ACM as an efficacy endpoint in patients receiving triple therapy. As ETHOS and ...
ACM over 52 weeks was statistically significantly reduced by 39% for BGF versus FF/UMEC/VI in the MAIC (hazard ratio [HR] [95% CI]: 0.61 [0.38, 0.95],...
In this MAIC, which adjusted for population heterogeneity between ETHOS and IMPACT, ACM was significantly reduced with BGF versus FF/UMEC/VI in patients with moderate-to-very severe COPD....
Mometasone Furoate (MF) is a corticosteroid (glucocorticoid) used to treat eczema, psoriasis, allergies, and rash on the skin; also used to reduce itching, redness, and swelling (inflammation). It has...
The goal of the study is to develop, a non-ionic surfactant-based vesicular system, by loading mometasone furoate, and introducing it into a gel-based formulation by utilizing an appropriate gelling a...
The niosome vesicle was prepared by vacuum rotary evaporation method (Thin film hydration method). Gel was prepared using the dispersion method and in-vitro drug diffusion studies using Franz-diffusio...
According to the results of the experiments conducted for the study, Mometasone Furoate niosomal gel was prepared utilizing Mometasone Furoate niosomes that were made using the thin film hydration pro...
The experiments carried out during the study led to the conclusion that the thin-film hydration method was suitable for the formation of the MF-niosomes by using Span 60 and Cholesterol (2:1). The gel...
The combination of an inhaled corticosteroid (ICS) and long-acting β-agonist (LABA) (ICS/LABA) has shown superiority in improving lung function (FEV...
We sought to compare the efficacy of 2 combinations of an ICS and LABA, namely, fluticasone propionate (FP) and formoterol (FORM) (FP/FORM) and fluticasone furoate (FF) and vilanterol (VI) (FF/VI), in...
FP/FORM (125 μg/5 μg, 2 doses twice daily via the k-haler [Mundipharma, Cambridge, UK]) and FF/VI (92 μg/22 μg, once daily via the Ellipta inhaler [GlaxoSmithKline]) were administered to adolescents a...
Both ICS/LABA combinations resulted in a significant improvement in FEV...
Both ICS/LABA combinations demonstrated significant improvements in FEV...
To observe the clinical effect of mometasone furoate cream sodium Alginate Skin Repair Mask in the treatment of atopic dermatitis (AD). By assessing the combined use of these two treatments, the study...
Eighty patients were enrolled, including 42 males and 38 females aged 20-47 years, with an average age of (32.52±5.57) years, from July 2021 to July 2022, and the patients were divided into a single g...
The total effective rate of the single group was 80.0% (32/40), and that of the combined group was 97.5% (39/40) (P < .05). After treatment, the skin lesion area score, skin lesion degree score, pruri...
Mometasone furoate cream sodium Alginate Skin Repair Mask has an ideal clinical effect in the treatment of atopic dermatitis. Compared with single mometasone furoate cream, the combination of sodium A...
Topical and systemic corticosteroids are the most effective medical treatment for nasal polyps, this study aims to systematically explore the efficacy and safety of mometasone furoate (MTF) for patien...
Osteosarcoma is the most common primary malignant bone tumor in adolescents. While treatments for osteosarcoma have improved, the overall survival has not changed for three decades, and thus, new targ...
The single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) is available for maintenance therapy of chronic obstructive pulmonary disease (C...
This double-blind, randomised, active- and placebo-controlled, crossover study recruited adults with COPD aged ≥ 40 years, who were hyperinflated and symptomatic, and were receiving mono- or dual inha...
Of 106 patients randomised, 95 completed the study. Resting IC adjusted mean differences vs. placebo were 315 and 223 mL for BDP/FF/G and BDP/FF, respectively (p < 0.001 for both). Adjusted mean diffe...
In patients with COPD, BDP/FF/G provided significant and clinically relevant improvements vs. placebo and BDP/FF in static and dynamic hyperinflation, with an improvement vs. placebo in exercise endur...
ClinicalTrials.gov (NCT05097014), registered 27th October 2021....